n addition to the total number of vascular events or deaths prevented, we did an additional analysis to be as conservative as possible in assessing net clinical benefit in which we allowed only the first vascular event to be counted for any trial participant; thus, in this additional analysis, a trial participant with non-fatal myocardial infarction, venous thromboembolism, non-fatal stroke, and death was counted as having one rather than four